头颈部鳞状细胞癌中USP10的表达及其预后价值

doi:10.13701/j.cnki.kqyxyj.2024.05.008

口腔医学研究 ›› 2024, Vol. 40 ›› Issue (5): 417-421.DOI: 10.13701/j.cnki.kqyxyj.2024.05.008

头颈部鳞状细胞癌中USP10的表达及其预后价值

梁登桓¹, 刘家琦¹, 李东慧¹, 张佳佳¹, 郭超杰¹, 曾妍^1,2, 徐江³, 郑军^3*

1.石河子大学医学院新疆石河子 832000;
2.广东医科大学湛江中心医院精准临床检验科广东湛江 524000;
3.石河子大学第一附属医院口腔科新疆石河子 832000

收稿日期:2023-11-14 出版日期:2024-05-28 发布日期:2024-05-22
通讯作者: * 郑军,E-mail: haohaoay@yeah.net
作者简介:梁登桓(1997~ ),男,河南周口人,硕士在读,主要从事口腔医学相关研究工作。
基金资助:
国家自然科学基金(编号:81560473);石河子大学科研资助基金(编号:CGZH202001)

Expression and Prognostic Value of USP10 in Head and Neck Squamous Cell Carcinoma

LIANG Denghuan¹, LIU Jiaqi¹, LI Donghui¹, ZHANG Jiajia¹, GUO Chaojie¹, ZENG Yan^1,2, XU Jiang³, ZHENG Jun^3*

1. School of Medicine, Shihezi University, Shihezi 832000, China;
2. Department of Precision Clinical Laboratory, Zhanjiang Central Hospital of Guangdong Medical University, Zhanjiang 524000, China;
3. Department of Stomatology, First Affiliated Hospital of Shihezi University, Shihezi 832000, China

Received:2023-11-14 Online:2024-05-28 Published:2024-05-22

摘要/Abstract

摘要： 目的:研究头颈鳞状细胞癌(head and neck squamous cell carcinoma,HNSCC)组织中泛素-特异性蛋白酶10(ubiquitin-specific peptidase 10,USP10)的表达情况并探讨其预后价值。方法:通过UALCAN网站分析HNSCC中USP10 mRNA和蛋白质的表达水平,采用免疫组织化学法检测70例HNSCC组织和30例正常组织中USP10蛋白的表达,分析HNSCC中USP10的表达与临床特征和预后的关系。结果:HNSCC组织中USP10表达上调(P＜0.05),且USP10的表达与分化程度相关(P＜0.05)。Kaplan-Meier分析结果显示,USP10高表达组生存时间短于低表达组(P＜0.05)。Cox回归分析结果显示,淋巴转移和USP10高表达是HNSCC患者预后不良的独立危险因素(P＜0.05)。结论:HNSCC中USP10表达升高,USP10可作为HNSCC的预后标志物。

关键词: 头颈部鳞状细胞癌, 泛素-特异性蛋白酶10, 预后

Abstract: Objective: To study the expression of USP10 and its prognostic value in head and neck squamous cell carcinoma (HNSCC). Methods: The UALCAN website was utilized to analyze the expression of USP10 mRNA and protein in HNSCC. The protein expression of USP10 was detected by immunohistochemical method in 70 HNSCC tissues and 30 normal tissues. The relationship between USP10 in HNSCC and clinical features and prognosis was analyzed. Results: The expression of USP10 was increased in HNSCC tissues (P<0.05), and the expression of USP10 was related to the degree of differentiation (P<0.05). Kaplan-Meier analysis results showed that the high USP10 expression group had a shorter survival time than the low expression group (P＜0.05). Cox regression analysis results showed that lymphatic metastasis and high USP10 expression was independent risk factors for poor prognosis in HNSCC patients (P＜0.05). Conclusion: The expression of USP10 is increased in HNSCC. USP10 may be a prognostic marker for HNSCC.

Key words: head and neck squamous cell carcinoma, USP10, prognosis

梁登桓, 刘家琦, 李东慧, 张佳佳, 郭超杰, 曾妍, 徐江, 郑军. 头颈部鳞状细胞癌中USP10的表达及其预后价值[J]. 口腔医学研究, 2024, 40(5): 417-421.

LIANG Denghuan, LIU Jiaqi, LI Donghui, ZHANG Jiajia, GUO Chaojie, ZENG Yan, XU Jiang, ZHENG Jun. Expression and Prognostic Value of USP10 in Head and Neck Squamous Cell Carcinoma[J]. Journal of Oral Science Research, 2024, 40(5): 417-421.

参考文献

[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2] Mccord C, Kiss A, Magalhaes MA, et al. Oral squamous cell carcinoma associated with precursor lesions [J]. Cancer Prev Res (Phila), 2021, 14(9): 873-884.
[3] Antao AM, Tyagi A, Kim KS, et al. Advances in deubiquitinating enzyme inhibition and applications in cancer therapeutics [J]. Cancers (Basel), 2020, 12(6): 1579.
[4] Aulas A, Finetti P, Lyons SM, et al. Revisiting the concept of stress in the prognosis of solid tumors: A role for stress granules proteins? [J]. Cancers (Basel), 2020, 12(9): 2470.
[5] Song D, Kuang L, Yang L, et al. Yin and yang regulation of stress granules by Caprin-1 [J]. Proc Natl Acad Sci U S A, 2022, 119(44): e2207975119.
[6] Yuan T, Chen Z, Yan F, et al. Deubiquitinating enzyme USP10 promotes hepatocellular carcinoma metastasis through deubiquitinating and stabilizing Smad4 protein [J]. Mol Oncol, 2020, 14(1): 197-210.
[7] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2018, 68(6): 394-424.
[8] Cramer JD, Burtness B, Le QT, et al. The changing therapeutic landscape of head and neck cancer [J]. Nat Rev Clin Oncol, 2019, 16(11): 669-683.
[9] Johnson DE, Burtness B, Leemans CR, et al. Head and neck squamous cell carcinoma [J]. Nat Rev Dis Primers, 2020, 6(1): 92.
[10] Liao Y, Liu N, Xia X, et al. USP10 modulates the SKP2/Bcr-Abl axis via stabilizing SKP2 in chronic myeloid leukemia [J]. Cell Discov, 2019, 30(5): 24.
[11] Li B, Qi ZP, He DL, et al. NLRP7 deubiquitination by USP10 promotes tumor progression and tumor-associated macrophage polarization in colorectal cancer [J]. J Exp Clin Cancer Res, 2021, 40(1): 126.
[12] Epstein JI, Amin MB, Fine SW, et al. The 2019 genitourinary pathology society (GUPS) white paper on contemporary grading of prostate cancer [J]. Arch Pathol Lab Med, 2021, 145(4): 461-493.
[13] Ren Z, Zhang L, Ding W, et al. Development and validation of a novel survival model for head and neck squamous cell carcinoma based on autophagy-related genes [J]. Genomics, 2021, 113(1 Pt 2): 1166-1175.
[14] Tao L, Liu X, Jiang X, et al. USP10 as a potential therapeutic target in human cancers [J]. Genes, 2022, 13(5): 831.
[15] Ma ZQ, Feng YT, Guo K, et al. Melatonin inhibits ESCC tumor growth by mitigating the HDAC7/beta-catenin/c-Myc positive feedback loop and suppressing the USP10-maintained HDAC7 protein stability [J]. Mil Med Res, 2022, 9(1): 54.
[16] Liao Y, Liu N, Xia X, et al. USP10 modulates the SKP2/Bcr-Abl axis via stabilizing SKP2 in chronic myeloid leukemia [J]. Cell Discov, 2019, 5(1):24.
[17] Ballar Kirmizibayrak P, Erbaykent-Tepedelen B, Gozen O, et al. Divergent modulation of proteostasis in prostate cancer [J]. Adv Exp Med Biol, 2020, 1233:117-151.
[18] Ouchida AT, Kacal M, Zheng A, et al. USP10 regulates the stability of the EMT-transcription factor Slug/SNAI2 [J]. Biochem Biophys Res Commun, 2018, 502(4): 429-434.
[19] Guo J, Zhang J, Liang L, et al. Potent USP10/13 antagonist spautin-1 suppresses melanoma growth via ROS-mediated DNA damage and exhibits synergy with cisplatin [J]. J Cell Mol Med, 2020, 24(7): 4324-4340.
[20] Ye Z, Chen J, Huang P, et al. Ubiquitin-specific peptidase 10, a deubiquitinating enzyme: Assessing its role in tumor prognosis and immune response [J]. Front Oncol, 2022, 12:990195.
[21] Liu J, Jin J, Liang T, et al. To Ub or not to Ub: a regulatory question in TGF-beta signaling [J]. Trends Biochem Sci, 2022, 47(12): 1059-1072.

头颈部鳞状细胞癌中USP10的表达及其预后价值

Expression and Prognostic Value of USP10 in Head and Neck Squamous Cell Carcinoma

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	卢芳, 宁彤彤, 王婕, 赵嘉, 房静, 宁倩倩, 李家锋. MYO5A 35号外显子跳跃对头颈鳞状细胞癌患者的预后相关研究[J]. 口腔医学研究, 2024, 40(3): 236-241.
[2]	房敏健, 刘亮, 邱若兰, 曹伟, 葛素云, 柴大敏. 肿瘤间质比在口腔鳞状细胞癌患者预后评估中的价值分析[J]. 口腔医学研究, 2024, 40(3): 242-247.
[3]	陈河林, 舒佳玉, 董强. CENPN对头颈鳞状细胞癌患者预后的预测价值研究[J]. 口腔医学研究, 2023, 39(8): 690-695.
[4]	杨可, 孙雅楠, 胡雅英, 吕宜楠, 郑小风, 李易玮, 张佳莉. cyclin D1表达模式深度学习识别和预测模型对HPV阴性口腔鳞状细胞癌和口咽鳞状细胞癌患者预后的预测作用[J]. 口腔医学研究, 2023, 39(4): 308-315.
[5]	李芷, 陈伟. Notch信号通路在腺样囊性癌中的研究进展[J]. 口腔医学研究, 2023, 39(12): 1042-1045.
[6]	郎雪莲, 胡涛. 恒牙活髓切断术-从基础到临床的新进展[J]. 口腔医学研究, 2023, 39(10): 866-870.
[7]	蒋志敏, 马国武, 孙波. Nomogram预测根治性切除局部晚期口腔鳞状细胞癌患者的预后[J]. 口腔医学研究, 2023, 39(1): 56-61.
[8]	张慧, 姜文敬, 王梦瑶, 李林林, 闫波, 高黎. 68例儿童恒牙外伤预后的回顾性研究[J]. 口腔医学研究, 2022, 38(7): 678-681.
[9]	吕宜楠, 胡雅英, 郑小风, 杨可, 张佳莉. IL-12A和EBI3在OSCC中的表达及其与免疫微环境的关系[J]. 口腔医学研究, 2022, 38(6): 533-539.
[10]	齐元莉, 闫红娟, 祖木热提古丽·阿不来提, 张超杰, 赵举红, 徐江. 口腔鳞状细胞癌中CASZ1的表达及临床意义[J]. 口腔医学研究, 2022, 38(1): 30-33.
[11]	周伟, 汤雅, 李厚轩, 陈斌, 闫福华. 牙周牙髓联合病变患牙预后观察的回顾性研究[J]. 口腔医学研究, 2021, 37(9): 825-829.
[12]	张旭, 刘佳文. MMP-9、COX-2、NF-κB在口腔鳞状细胞癌组织中的表达及意义[J]. 口腔医学研究, 2021, 37(4): 360-365.
[13]	杨凯成, 杨蕾, 赵建广, 罗风玉, 陈彦平, 崔子峰, 陈赫, 满莎莎. 口腔鳞状细胞癌患者外周血microRNA的表达及预后意义[J]. 口腔医学研究, 2020, 36(5): 428-432.
[14]	孙振龙, 薛鹏, 遆云飞. 牙根发育完成自体牙移植远期预后及影响因素分析[J]. 口腔医学研究, 2020, 36(5): 449-453.
[15]	邹会会, 徐文光, 尹西腾, 韩伟, 江琳琳. 基于SEER数据库分析影响大唾液腺腺样囊性癌患者预后的临床病理因素[J]. 口腔医学研究, 2020, 36(2): 167-171.